Announcements Trials
Browse Landscape

Phase

Phase 2 32Phase 1 20Phase 1/2 8Phase 2/3 2Phase NA 1Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 4Renal Insufficiency 1Primary Myelofibrosis 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Breast Neoplasms 1

Interventions

Rituximab 5fludarabine 4Cyclophosphamide 4pembrolizumab 2Bendamustine Hydrochloride 268Ga-pentixafor 2venetoclax 1pegylated granulocyte colony-stimulating factor, human 1pegfilgrastim 1motexafin gadolinium 1ibrutinib 1fludarabine phosphate 1daratumumab 1brexucabtagene autoleucel 1acalabrutinib 1Vincristine 1Valproic Acid 1Transplantation 1Tablets 1Surveys and Questionnaires 1Sugars 1Stem Cell Transplantation 1Simvastatin 1Roflumilast 1Ribavirin 1Radiotherapy 1Procarbazine 1Positron-Emission Tomography 1Pemetrexed 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Lymphoma × Bortezomib × Clear all
NCT01171092 2017-01-11

A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma

University of Kansas Medical Center

Phase EARLY_PHASE1 Completed
21 enrolled
LymphoidPlasma cell

Lymphoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡